Parkinson’s Progression Markers Initiative
Contributing to a landmark study in Parkinson’s disease to identify biomarkers of disease progression
What is the Parkinson's Progression Markers Initiative?
The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal research study aiming to identify biomarkers of Parkinson’s disease and its progression. The study is led by the Michael J. Fox Foundation for Parkinson’s Research, and Verily joined as a research partner in 2018. This is one of two longitudinal Parkinson’s research programs that Verily is supporting. The other is the Personalized Parkinson's Project.
How are you making it happen?
We’ve built devices, algorithms and analytic outputs that capture relevant and reliable measurements from the human body to aid in the diagnosis and management of conditions like Parkinson’s disease. Parkinson’s disease looks different from person to person, and within the same person from hour to hour, so it’s important to develop reliable methods for capturing information continuously and over time.
For the PPMI study, we’re using the investigational Verily Study Watch to collect new data types and identify digital biomarkers, which have the potential to enhance researchers’ abilities to better define diagnostic markers and Parkinson’s disease progression. Ultimately, we hope to help researchers and therapeutic partners accelerate the development of treatments and support clinicians with better real-time disease monitoring to guide treatment and improve outcomes.